Syed Tabish Razi Zaidi

Prof. Syed Tabish Razi Zaidi


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
KLKah Seng Lee
Kah Seng Lee
SYSiew Mei Yee
Siew Mei Yee
SZSyed Tabish Razi Zaidi
Syed Tabish Razi Zaidi
RPRahul P. Patel
Rahul P. Patel
QYQuan Yang
Quan Yang
Long MingLong Ming
Long Ming
Combating Sale of Counterfeit and Falsified Medicines Online: A Losing Battle

31 January 2018 in Medical Principles and Practice
Verified
Journal Article
Open access
PDF file
YAYaser Al-Worafi
Yaser Al-Worafi
RPRahul P. Patel
Rahul P. Patel
SZSyed Tabish Razi Zaidi
Syed Tabish Razi Zaidi
WAWafa Mohammed Alseragi
Wafa Mohammed Alseragi
MAMasaad Saeed Almutairi
Masaad Saeed Almutairi
Long MingLong Ming
Long Ming
Objective: The aim of this study was to investigate the completeness and legibility of prescriptions dispensed in community pharmacies located in Sana’a, Yemen. Materials and Methods: A cross-sectional study was conducted at 23 randomly selected community pharmacies throughout the capital city of Sana’a, Yemen, from May 2015 to January 2016. A total of 2,178 prescriptions were analyzed for the essential elements of a complete prescription using a validated checklist. Results: Of the 2,178 prescriptions, 19 (0.87%) were considered to be of good quality. The remaining 2,159 (99.12%) were considered as being of very poor quality. Writing errors relating to patients and prescribed medications were the most common errors. Conclusion: In this study, the quality of prescription writing was found to be very poor. Hence, continuous professional development programs are recommended to improve the quality of prescription writing among physicians. Future studies in other cities and investigation of the impact of continuous educational programs on the quality of prescription writing are strongly recommended.

29 September 2020 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
Syed Shahzad HasanSyed Shahzad Hasan
Syed Shahzad Hasan
TCToby Capstick
Toby Capstick
RARaees Ahmed
Raees Ahmed
CKChia Siang Kow
Chia Siang Kow
FMFaizan Mazhar
Faizan Mazhar
SZSyed Tabish Razi Zaidi
Syed Tabish Razi Zaidi
The acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis is one of the main causes of high mortality in COVID-19 patients. We systematically reviewed ARDS-associated mortality ...

1 January 2020 in Patient Education and Counseling
Verified
Journal Article
Closed access
IKIsraa Khaleel
Israa Khaleel
BWBarbara C. Wimmer
Barbara C. Wimmer
GPGregory M. Peterson
Gregory M. Peterson
SZSyed Tabish Razi Zaidi
Syed Tabish Razi Zaidi
ERErin Roehrer
Erin Roehrer
Kenneth LeeKenneth Lee
Kenneth Lee

4 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SGSaurav Ghimire
Saurav Ghimire
RCRonald L. Castelino
Ronald L. Castelino
NLNicole M. Lioufas
Nicole M. Lioufas
Gregory PetersonGregory Peterson
Gregory Peterson
SZSyed Tabish Razi Zaidi
Syed Tabish Razi Zaidi
End-stage kidney disease (ESKD) patients are often prescribed multiple medications. Together with a demanding weekly schedule of dialysis sessions, increased number of medicines and associated regimen complexity pre-dispose them at high risk of medication nonadherence. This review summarizes existing literature on nonadherence and identifies factors associated with nonadherence to medication therapy in patients undergoing haemodialysis. A comprehensive search of PubMed, Embase, CINAHL, PsycInfo, and Cochrane Database of Systematic Reviews covering the period from 1970 through November 2014 was performed following a predefined inclusion and exclusion criteria. Reference lists from relevant materials were reviewed. Data on study characteristics, measures of nonadherence, prevalence rates and factors associated with nonadherence were collected. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was followed in conducting this systematic review. Of 920 relevant publications, 44 were included. The prevalence of medication nonadherence varied from 12.5% to 98.6%, with widespread heterogeneity in measures and definitions employed. Most common patient-related factors significantly associated with nonadherence were younger age, non-Caucasian ethnicity, illness interfering family life, being a smoker, and living single and being divorced or widowed. Similarly, disease-related factors include longevity of haemodialysis, recurrent hospitalization, depressive symptoms and having concomitant illness like diabetes and hypertension. Medication-related factors such as daily tablet count, total pill burden, number of phosphate binders prescribed and complexity of medication regimen were also associated with poor adherence. A number of patient-, disease-, and medication-related factors are associated with medication nonadherence in haemodialysis patients. Clinicians should be aware of such factors so that adherence to medications can be optimised in haemodialysis patients. Future research should be directed towards well-designed prospective longitudinal studies developing standard definitions and validating available measurement tools, while focusing on the role of additional factors such as psychosocial and behavioural factors in predicting nonadherence to medications.

21 August 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
DSDeepali Sharma
Deepali Sharma
RPRahul P. Patel
Rahul P. Patel
SZSyed Tabish Razi Zaidi
Syed Tabish Razi Zaidi
Md Moklesur Rahman SarkerMd Moklesur Rahman Sarker
Md Moklesur Rahman Sarker
QLQi Ying Lean
Qi Ying Lean
Long MingLong Ming
Long Ming
Ciprofloxacin, a second-generation broad spectrum fluoroquinolone, is active against both Gram-positive and Gram-negative bacteria. Ciprofloxacin has a high oral bioavailability and a large volume of distribution. It is used for the treatment of a wide range of infections including urinary tract infections caused by susceptible bacteria. However, the substandard and spurious quality of oral ciprofloxacin formulations in the developing countries has been thought to have contributed towards increased risk of treatment failure and bacterial resistance. Therefore, quality control and bioequivalence studies of the commercially available oral ciprofloxacin formulations should be monitored. Appropriate actions should be taken against offending manufacturers in order to prevent the sale of substandard medications, especially the spurious oral ciprofloxacin products.